2026 Pediatric Rheumatology Symposium

March 18-21, 2026. Minneapolis, MN.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 115

KneeMS for Juvenile Idiopathic Arthritis
Abstract Number: 001

Longitudinal Cardiovascular Profiles of Youth with Childhood-onset Systemic Lupus Erythematosus
Abstract Number: 025

Longitudinal Single Cell Transcriptomic Analysis of Type I and II Interferon (IFN) Response Genes (IRG) in Refractory Juvenile Dermatomyositis (JDM) Patients with Baricitinib Treatment
Abstract Number: 011

Lung Transplant for Pediatric Dermatomyositis Patients with Interstitial Lung Disease: A Single-Center Experience
Abstract Number: 005

Magnetic Resonance Enterography Detected Sacroiliitis in Pediatric Crohn’s Disease: A Retrospective Cohort Study
Abstract Number: 021

Medication Changes and Lung Disease Activity in Systemic JIA: Six-Month Follow-Up of CARRA Registry SJIA-LD Cohort
Abstract Number: 022

Mental Health concerns in Patients with Juvenile Idiopathic Arthritis and Their Caregivers: A Systematic Review
Abstract Number: 032

Methotrexate Response in Systemic JIA: Real-World Evidence from a Tertiary-Care Cohort
Abstract Number: 042

Mindfulness Matters: Early Insights from the Making Mindfulness Matter© in children with Juvenile Idiopathic Arthritis Study.
Abstract Number: 134

More Than Meets the Eye: Broadening the Clinical Spectrum of RelA Haploinsufficiency
Abstract Number: 030

Musculoskeletal and Nail Ultrasound Findings in Children with Psoriasis: A Case-Control Study
Abstract Number: 049

Novel Insights of Brain MRI Features in Neonatal Lupus Erythematosus with Hydrocephalus
Abstract Number: 015

Obinutuzumab Induces Histologic Remission And Deep Kidney Parenchymal B-Cell Depletion In Patients With Lupus Nephritis: Exploratory Analyses From The REGENCY Trial
Abstract Number: 037

Off-the-Shelf Anti-CD19 CAR T-cell Therapy with Reduced or No Conditioning Chemotherapy Demonstrates Efficacy and Tolerability in Systemic Lupus Erythematosus: Meaningful Activity Supports Planned Adolescent Enrollment
Abstract Number: 082

Ophthalmic Predictors of Response to Methotrexate Monotherapy in Pediatric Non-Infectious Uveitis

« Previous Page
1
…
4
5
6
7
8
…
10
Next Page »

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].